{
  "generated": "2025-11-06T07:16:45.094505+00:00",
  "policy_fingerprint": "0x6036438e1b958d88",
  "source_evidence": "entries/metabolic/resveratrol-long-lon03/longevity/v1/evidence.csv",
  "preferred_citation": "Kim G. TERVYX Protocol v1.0 (2025).",
  "studies": [
    {
      "study_id": "LONG-LON03_01",
      "year": 2018,
      "design": "randomized controlled trial",
      "journal": "longevity_journal",
      "outcome": "telomere_support",
      "population": "Adults with telomere support concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/resveratrol-long-lon03-01",
      "url": "https://doi.org/10.1234/resveratrol-long-lon03-01",
      "citation": "LONG-LON03_01 (2018); Journal: longevity_journal; Design: randomized controlled trial; Population: Adults with telomere support concerns; Outcome: telomere_support; DOI: 10.1234/resveratrol-long-lon03-01; Adverse Events: None reported."
    },
    {
      "study_id": "LONG-LON03_02",
      "year": 2019,
      "design": "randomized controlled trial",
      "journal": "longevity_journal",
      "outcome": "telomere_support",
      "population": "Adults with telomere support concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/resveratrol-long-lon03-02",
      "url": "https://doi.org/10.1234/resveratrol-long-lon03-02",
      "citation": "LONG-LON03_02 (2019); Journal: longevity_journal; Design: randomized controlled trial; Population: Adults with telomere support concerns; Outcome: telomere_support; DOI: 10.1234/resveratrol-long-lon03-02; Adverse Events: None reported."
    },
    {
      "study_id": "LONG-LON03_03",
      "year": 2020,
      "design": "randomized controlled trial",
      "journal": "longevity_journal",
      "outcome": "telomere_support",
      "population": "Adults with telomere support concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/resveratrol-long-lon03-03",
      "url": "https://doi.org/10.1234/resveratrol-long-lon03-03",
      "citation": "LONG-LON03_03 (2020); Journal: longevity_journal; Design: randomized controlled trial; Population: Adults with telomere support concerns; Outcome: telomere_support; DOI: 10.1234/resveratrol-long-lon03-03; Adverse Events: None reported."
    }
  ],
  "references": [
    {
      "type": "doi",
      "identifier": "10.1234/resveratrol-long-lon03-01",
      "study_ids": [
        "LONG-LON03_01"
      ],
      "primary_study_id": "LONG-LON03_01",
      "url": "https://doi.org/10.1234/resveratrol-long-lon03-01"
    },
    {
      "type": "doi",
      "identifier": "10.1234/resveratrol-long-lon03-02",
      "study_ids": [
        "LONG-LON03_02"
      ],
      "primary_study_id": "LONG-LON03_02",
      "url": "https://doi.org/10.1234/resveratrol-long-lon03-02"
    },
    {
      "type": "doi",
      "identifier": "10.1234/resveratrol-long-lon03-03",
      "study_ids": [
        "LONG-LON03_03"
      ],
      "primary_study_id": "LONG-LON03_03",
      "url": "https://doi.org/10.1234/resveratrol-long-lon03-03"
    }
  ],
  "manifest_hash": "sha256:c3efb0cd03902d5df56254d49e08422e9bb334e508260d5c65dec8319ac5b14a"
}
